JP2020500168A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020500168A5 JP2020500168A5 JP2019521720A JP2019521720A JP2020500168A5 JP 2020500168 A5 JP2020500168 A5 JP 2020500168A5 JP 2019521720 A JP2019521720 A JP 2019521720A JP 2019521720 A JP2019521720 A JP 2019521720A JP 2020500168 A5 JP2020500168 A5 JP 2020500168A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- composition according
- fraction
- excipient
- granule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 51
- 239000008187 granular material Substances 0.000 claims description 22
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 12
- 239000000654 additive Substances 0.000 claims description 8
- 230000000996 additive effect Effects 0.000 claims description 8
- 208000031886 HIV Infections Diseases 0.000 claims description 7
- 208000037357 HIV infectious disease Diseases 0.000 claims description 7
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims description 7
- 239000004480 active ingredient Substances 0.000 claims description 6
- 239000007884 disintegrant Substances 0.000 claims description 6
- YIBOMRUWOWDFLG-ONEGZZNKSA-N rilpivirine Chemical compound CC1=CC(\C=C\C#N)=CC(C)=C1NC1=CC=NC(NC=2C=CC(=CC=2)C#N)=N1 YIBOMRUWOWDFLG-ONEGZZNKSA-N 0.000 claims description 6
- 239000000080 wetting agent Substances 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- 229960002814 rilpivirine Drugs 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 239000011230 binding agent Substances 0.000 claims 3
- 229920002785 Croscarmellose sodium Polymers 0.000 claims 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 2
- 229960001681 croscarmellose sodium Drugs 0.000 claims 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 1
- 229920001213 Polysorbate 20 Polymers 0.000 claims 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims 1
- 239000008383 extra-granule composition Substances 0.000 claims 1
- 229960001021 lactose monohydrate Drugs 0.000 claims 1
- 239000000314 lubricant Substances 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 1
- 239000008108 microcrystalline cellulose Substances 0.000 claims 1
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims 1
- 229940068977 polysorbate 20 Drugs 0.000 claims 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022165319A JP2023011659A (ja) | 2016-10-24 | 2022-10-14 | 分散性組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201621036404 | 2016-10-24 | ||
| IN201621036404 | 2016-10-24 | ||
| PCT/EP2017/077030 WO2018077815A1 (en) | 2016-10-24 | 2017-10-23 | Dispersible compositions |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022165319A Division JP2023011659A (ja) | 2016-10-24 | 2022-10-14 | 分散性組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020500168A JP2020500168A (ja) | 2020-01-09 |
| JP2020500168A5 true JP2020500168A5 (enExample) | 2020-12-10 |
| JP7197474B2 JP7197474B2 (ja) | 2022-12-27 |
Family
ID=60262899
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019521720A Active JP7197474B2 (ja) | 2016-10-24 | 2017-10-23 | 分散性組成物 |
| JP2022165319A Withdrawn JP2023011659A (ja) | 2016-10-24 | 2022-10-14 | 分散性組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022165319A Withdrawn JP2023011659A (ja) | 2016-10-24 | 2022-10-14 | 分散性組成物 |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US11065198B2 (enExample) |
| EP (2) | EP3528791B1 (enExample) |
| JP (2) | JP7197474B2 (enExample) |
| KR (2) | KR102861006B1 (enExample) |
| CN (1) | CN110191704A (enExample) |
| CA (1) | CA3039562A1 (enExample) |
| DK (1) | DK3528791T3 (enExample) |
| ES (1) | ES2970870T3 (enExample) |
| FI (1) | FI3528791T3 (enExample) |
| HR (1) | HRP20240118T1 (enExample) |
| HU (1) | HUE064823T2 (enExample) |
| LT (1) | LT3528791T (enExample) |
| MA (1) | MA46563B1 (enExample) |
| MX (1) | MX2019004767A (enExample) |
| PL (1) | PL3528791T3 (enExample) |
| PT (1) | PT3528791T (enExample) |
| RS (1) | RS65159B1 (enExample) |
| SI (1) | SI3528791T1 (enExample) |
| SM (1) | SMT202400060T1 (enExample) |
| TW (1) | TWI821163B (enExample) |
| WO (1) | WO2018077815A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022538338A (ja) * | 2019-07-03 | 2022-09-01 | ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー | リルピビリンを用いて小児患者におけるｈｉｖを治療する方法 |
| WO2021104487A1 (en) | 2019-11-29 | 2021-06-03 | Aptorum Therapeutics Limited | Composition including rilpivirine and use thereof for treating tumors or cancer |
| WO2021253380A1 (en) * | 2020-06-19 | 2021-12-23 | InventisBio Co., Ltd. | Oral formulations and uses thereof |
| CN114392241B (zh) * | 2022-01-10 | 2023-07-25 | 安徽贝克生物制药有限公司 | 一种利匹韦林片及其制备方法 |
| GB202211231D0 (en) * | 2022-08-02 | 2022-09-14 | Glaxosmithkline Ip No 2 Ltd | Novel formulation |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0181966A1 (en) * | 1984-11-13 | 1986-05-28 | Gist-Brocades N.V. | Compression-coated dispersible tablets |
| GB9109862D0 (en) * | 1991-05-08 | 1991-07-03 | Beecham Lab Sa | Pharmaceutical formulations |
| JO3429B1 (ar) | 2001-08-13 | 2019-10-20 | Janssen Pharmaceutica Nv | مشتقات برميدينات مثبطة فيروس الايدز |
| MY169670A (en) | 2003-09-03 | 2019-05-08 | Tibotec Pharm Ltd | Combinations of a pyrimidine containing nnrti with rt inhibitors |
| CN101481356B (zh) | 2002-08-09 | 2012-07-11 | 詹森药业有限公司 | 制备4-[[4-[[4-(2-氰基乙烯基)-2,6-二甲基苯基]氨基]-2-嘧啶基]氨基]苄腈的方法 |
| KR101284361B1 (ko) | 2004-09-02 | 2013-07-15 | 얀센 파마슈티카 엔.브이. | 4-((4-((4-(2-시아노에텐일)-2,6-디메틸페닐)아미노-2-피리미딘일)아미노)벤조니트릴의 하이드로클로라이드 |
| EP1632232B3 (en) * | 2004-09-02 | 2022-03-30 | Janssen Pharmaceutica NV | Salt of 4[[4-[[4-(2-Cyanoethenyl)-2,6-dimethylphenyl]amino]-2-Pyrimidinyl]amino]benzonitrile |
| CN101056673A (zh) * | 2004-09-02 | 2007-10-17 | 詹森药业有限公司 | 4－[[4－[[4－(2－氰基乙烯基)－2,6－二甲基苯基]氨基]－2－嘧啶基]氨基]苄腈的盐酸盐 |
| AP2618A (en) | 2006-06-23 | 2013-03-18 | Tibotec Pharmaceutical Ltd | Aqueous suspensions of TMC278 |
| WO2015120014A1 (en) | 2014-02-05 | 2015-08-13 | Merck Sharp & Dohme Corp. | Novel disintegration systems for pharmaceutical dosage forms |
| WO2015136294A1 (en) * | 2014-03-13 | 2015-09-17 | Cipla Limited | Pharmaceutical composittion comprising rilpivirine |
| EP3142640A1 (en) | 2014-05-16 | 2017-03-22 | Vivus, Inc. | Orally disintegrating dosage form for administration of avanafil, and associated methods of manufacture and use |
-
2017
- 2017-10-23 CA CA3039562A patent/CA3039562A1/en active Pending
- 2017-10-23 SM SM20240060T patent/SMT202400060T1/it unknown
- 2017-10-23 WO PCT/EP2017/077030 patent/WO2018077815A1/en not_active Ceased
- 2017-10-23 MA MA46563A patent/MA46563B1/fr unknown
- 2017-10-23 SI SI201731486T patent/SI3528791T1/sl unknown
- 2017-10-23 US US16/344,143 patent/US11065198B2/en active Active
- 2017-10-23 HR HRP20240118TT patent/HRP20240118T1/hr unknown
- 2017-10-23 JP JP2019521720A patent/JP7197474B2/ja active Active
- 2017-10-23 KR KR1020247001197A patent/KR102861006B1/ko active Active
- 2017-10-23 EP EP17794275.2A patent/EP3528791B1/en active Active
- 2017-10-23 LT LTEPPCT/EP2017/077030T patent/LT3528791T/lt unknown
- 2017-10-23 FI FIEP17794275.2T patent/FI3528791T3/fi active
- 2017-10-23 KR KR1020197014202A patent/KR20190073450A/ko not_active Ceased
- 2017-10-23 MX MX2019004767A patent/MX2019004767A/es unknown
- 2017-10-23 CN CN201780065671.8A patent/CN110191704A/zh active Pending
- 2017-10-23 EP EP23169649.3A patent/EP4248947A3/en active Pending
- 2017-10-23 DK DK17794275.2T patent/DK3528791T3/da active
- 2017-10-23 ES ES17794275T patent/ES2970870T3/es active Active
- 2017-10-23 HU HUE17794275A patent/HUE064823T2/hu unknown
- 2017-10-23 PL PL17794275.2T patent/PL3528791T3/pl unknown
- 2017-10-23 RS RS20240158A patent/RS65159B1/sr unknown
- 2017-10-23 PT PT177942752T patent/PT3528791T/pt unknown
- 2017-10-24 TW TW106136552A patent/TWI821163B/zh active
-
2021
- 2021-06-15 US US17/347,929 patent/US20220008333A1/en not_active Abandoned
-
2022
- 2022-10-14 JP JP2022165319A patent/JP2023011659A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020500168A5 (enExample) | ||
| US8309126B2 (en) | Dispersible bosentan tablet | |
| FI3265084T3 (fi) | Brutonin tyrosiinikinaasin estäjän lääkeformulaatioita | |
| TWI583384B (zh) | 包含４－胺基－５－氟－３－［６－（４－甲基哌嗪－１－基）－１ｈ－苯并咪唑－２－基］－１ｈ－喹啉－２－酮乳酸鹽單水合物之醫藥組合物 | |
| CN107530348B (zh) | 一种含有jak激酶抑制剂或其可药用盐的药物组合物 | |
| JP2017528503A5 (enExample) | ||
| JP2014533733A5 (enExample) | ||
| JP2015511621A5 (enExample) | ||
| RU2019122414A (ru) | Антивирусные алифатические сложноэфирные пролекарства тенофовира | |
| NZ627963A (en) | Dry powder pharmaceutical formulations for inhalation of a compound that inhibits pi3 kinase | |
| US20150104511A1 (en) | Pharmaceutical Antiretroviral Combinations Comprising Lamivudine, Festinavir and Nevirapine | |
| JP2019536812A5 (enExample) | ||
| RU2018136580A (ru) | Цитратная соль (s)-4-((s)-3-фтор-3-(2-(5,6,7,8-тетрагидро-1,8-нафтиридин-2-ил)этил)пирролидин-1-ил)-3-(3-(2-метоксиэтокси)фенил)бутановой кислоты | |
| FI3528791T3 (fi) | Dispergoituvia koostumuksia | |
| JP2010520891A (ja) | ネビラピンの徐放性製剤 | |
| FI3389638T3 (fi) | Pimobendaania käsittävä lääkekoostumus | |
| JP2015534985A5 (enExample) | ||
| WO2021091498A1 (en) | Pharmaceutical compositions comprising tenofovir and emtricitabine | |
| JP2018184382A (ja) | エゼチミブ含有錠剤およびその製法 | |
| ZA202200331B (en) | Naltrexone formulation | |
| EP3518935A1 (en) | Therapeutic compositions for treatment of human immunodeficiency virus | |
| JP2018184381A (ja) | エゼチミブ含有錠剤およびその製法 | |
| WO2013154512A1 (en) | Pharmaceutical formulations comprising dexibuprofen | |
| JP2010516712A5 (enExample) | ||
| ES2875405T3 (es) | Composición farmacéutica que comprende darunavir y método para su preparación |